Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Fast-TRACKing precision oncology for rare cancers: A national decentralized trial offering comprehensive genomic profiling and a molecular tumor board.

Jim Palma, Shumei Kato, Mina Nikanjam et al. Jun 01, 2026 pp. 3147-3147 10.1200/jco.2026.44.16_suppl.3147

3147 Background: The TargetCancer Foundation TCF-001 TRACK study (Target RAre Cancer Knowledge, NCT04504604) initiated on...

Sleep disorders in cancer survivors: A cross-sectional study from Morocco.

Sara Nejjari, Mehdi Alem, Diango Keita et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24133

e24133 Background: Sleep disturbances are among the most frequent and burdensome symptoms in patients with cancer and ofte...

Racial representation in clinical trials supporting NCCN breast cancer guidelines: A retrospective analysis.

Shreya Motkur, Niket Shah, Naomi Shah et al. Jun 01, 2026 pp. 1651-1651 10.1200/jco.2026.44.16_suppl.1651

1651 Background: Racial disparities in breast cancer are well established, with Black women having disproportionately high...

A phase III multicenter randomized non-inferiority trial comparing selective versus modified neck dissection in node-positive oral squamous cell carcinoma (SND vs MND).

Rakesh Katna, Priyal Patil, Sweta Parida et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps6133

TPS6133 Background: Neck dissection is a critical component in the management of oral squamous cell carcinoma (OSCC) with...

A clinically applicable toolkit for cervical gastric-type adenocarcinoma: Diagnostic model, predictive survival nomograms, and risk stratification.

Junjun Qiu, Xinqu Qu, Xingyu Chang et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17509

e17509 Background: Cervical gastric-type adenocarcinoma (GAS), an aggressive non-HPV-associated malignancy, is often misdi...

Trends in mortality and disparities in small intestine neoplasms among U.S. adults aged 65 years and older: A retrospective analysis of 25 years.

Irza Shaikh, Sarim Hassan Shahab, Hadia Ghazala Masood et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15684

e15684 Background: Small intestine neoplasms are relatively rare malignancies but contribute to a growing cancer-related m...

JSKN016, a first-in-class anti-TROP2/HER3 bispecific antibody-drug conjugate (ADC), in patients (pts) with HER2-negative locally advanced or metastatic breast cancer: Results from a phase I study.

Herui Yao, Zhangzhou Huang, Hong Zong et al. Jun 01, 2026 pp. 1123-1123 10.1200/jco.2026.44.16_suppl.1123

1123 Background: TROP2 and HER3 are frequently overexpressed in most of solid tumors. JSKN016 is a first-in-class bispecif...

AI-assisted systematic review and pooled analysis of anthracycline- versus taxane-based chemotherapy in advanced or metastatic angiosarcoma.

Annarita Peddio, Simeone D'Ambrosio, Filippo Vitale et al. Jun 01, 2026 pp. 11522-11522 10.1200/jco.2026.44.16_suppl.11522

11522 Background: Comparative evidence for first-line anthracycline- (Ant) vs taxane-based (Tax) chemotherapy in advanced...

A first-in-human phase I clinical trial evaluating the safety, tolerability, and preliminary efficacy of the novel fas ligand (FasL) inhibitor M3T01 in adults with advanced solid tumors.

Rom S. Leidner, Prakash Ambady, Emily Lin et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps2670

TPS2670 Background: Tumor-specific T cells undergo apoptotic cell death following FasL binding to the fas (CD95) receptor....

New paradigm for antibiotic selection in hard-to-treat drug-resistant infections following HSCT.

George Tetz, Kristina Kardava, Maria Vecherkovskaya et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18627

e18627 Background: HSCT patients are highly susceptible to severe infections. Conventional antimicrobial susceptibility te...

Tumor-informed versus tumor-agnostic ctDNA assays for molecular residual disease detection in colorectal cancer: A systematic review and meta-analysis.

Nain Tara, Hina Zubair, Abdullah Sultany et al. Jun 01, 2026 pp. 3595-3595 10.1200/jco.2026.44.16_suppl.3595

3595 Background: Circulating tumor DNA (ctDNA) is increasingly used for detection of molecular residual disease (MRD) foll...

Impact of time-of-day (ToD) of single-agent immune-checkpoint inhibitor (ICI) on survival in advanced non–small cell lung cancer (aNSCLC) with PD-L1 ≥ 50%: Analysis of the NOTCH collaborative REAL-SAIF study.

Alfred Chung Pui So, Mary Denholm, Stephen David Robinson et al. Jun 01, 2026 pp. 8602-8602 10.1200/jco.2026.44.16_suppl.8602

8602 Background: There is growing evidence and interest in the role of chrono-immunotherapy. Previous studies showing bene...

Efficacy and safety of immune checkpoint inhibitor rechallenge in advanced hepatocellular carcinoma: A systematic review and meta-analysis.

FNU Deeksha, Sai Sushrutha Mudupula Vemula, Ahsun Rizwan Siddiqi et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16192

e16192 Background: Immune checkpoint inhibitors (ICIs) are integral to the treatment of advanced hepatocellular carcinoma...

Multiomic profiling of early onset colorectal cancer in an irish tertiary cancer centre: Outcomes and correlative insights.

Mary O. Reilly, Kieran Sheahan, Kieran Wynne et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15643

e15643 Background: Colorectal cancer (CRC) is a major global health concern as it is the second most fatal cancer worldwid...

National disparities in outcomes among hospitalizations for myelodysplastic syndromes complicated by sepsis: The impact of insurance, hospital type, and geographic region.

Muhammad Dawood Amir Sheikh, Muhammad Areeb Ashfaq, Daisy E. Escobar et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18583

e18583 Background: Prior studies show that sepsis outcomes vary by insurance, hospital type, and geographic location; howe...

A phase 1b/2 study of AK130 (TIGIT/TGF-β bispecific fusion protein) combined with ivonescimab in advanced biliary tract cancer (BTC).

Haitao Zhao, Tongsen Zheng, Xiaobo Yang et al. Jun 01, 2026 pp. 4142-4142 10.1200/jco.2026.44.16_suppl.4142

4142 Background: Chemotherapy (chemo) combined with or without PD-(L)1 inhibition is the standard first-line treatment for...

Efficacy and safety of TACE with or without MWA followed by sequential targeted and immunotherapy in HCC beyond the up-to-7 criteria.

Yang Fang, Chunhua Quan, Jiangyu Tan et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16288

e16288 Background: Although accumulating evidence suggests survival benefits of transarterial chemoembolization (TACE) com...

Efficacy and safety of PD-1 inhibitor plus chemotherapy vs chemotherapy alone in advanced gastric cancer patients with low or negative PD-L1 expression.

Abdallah Al Ghnaimat, Sana Shaik, Shifa Mohamed Rafi et al. Jun 01, 2026 pp. 4041-4041 10.1200/jco.2026.44.16_suppl.4041

4041 Background: Advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma remains a major global health challen...

Intracranial activity of trastuzumab deruxtecan in HER2-low breast cancer with brain metastases: A systematic review and meta-analysis.

Shreya Ghanshyam Patel, Vasu Malhotra, Sravani Bhavanam et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13082

e13082 Background: Human epidermal growth factor receptor 2 (HER2)–low breast cancer, defined as HER2 immunohistochemistry...

ASC4FIRST wk 144 analysis: Efficacy and safety and tolerability with asciminib (ASC) vs investigator-selected tyrosine kinase inhibitors (IS TKIs) in newly diagnosed (ND) chronic myeloid leukemia in chronic phase (CML-CP).

Jorge E. Cortes, Andreas Hochhaus, Naoto Takahashi et al. Jun 01, 2026 pp. 6583-6583 10.1200/jco.2026.44.16_suppl.6583

6583 Background: In ASC4FIRST (NCT04971226) primary (wk 48) (Hochhaus A et al. N Engl J Med...

Self-reported ethnicity and outcomes of newly diagnosed multiple myeloma (NDMM) in the anti-CD38 monoclonal antibody era: A retrospective cohort study.

Michael Sang Hughes, Andrew Doyle, Nadiya Yehxin Koth et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e19554

e19554 Background: Multiple myeloma has a well known disparity in incidence between non-Hispanic Black (NHB) and non-Hispa...

Impact of venetoclax dosing on outcomes in AML: A single-center real-world study.

Cheryl H. Chang, Allison O. Taylor, Nia Michaela Mitchell et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18511

e18511 Background: VIALE-A established Aza and Venetoclax (Ven) as first-line therapy (1L) for acute myeloid leukemia for...

Dietary supplement use among adult cancer survivors: Results from a large cross-sectional study in Poland.

Miroslawa Puskulluoglu, Anna Zimny-Zajac, Renata Pacholczak-Madej et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13782

e13782 Background: Dietary supplement use is common among adults with a history of cancer and may reflect unmet needs and...

Integrated tissue transcriptome deconvolution of grade-associated tumor microenvironment patterns in CNS tumors.

Shriniwas Subhash Kulkarni, Shina Goyal, Vivek Agarwala et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e14039

e14039 Background: Central nervous system (CNS) tumors exhibit marked tumor microenvironment (TME) heterogeneity, includin...

Intrathecal (IT) PD-1/CTLA-4 antibody combined with pemetrexed (PM) for leptomeningeal metastases (LM) from solid tumors: Preliminary results of two single-center phase I studies.

Zhenyu Pan, Guozi Yang, Yushan Huang et al. Jun 01, 2026 pp. 2624-2624 10.1200/jco.2026.44.16_suppl.2624

2624 Background: IT PD-1 inhibitors, alone or combined with IT PM, have shown safety and feasibility in LM from solid tumo...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page